Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 5-year post-marketing safety study for dalfampridine extended release tablets in multiple sclerosis

Next Previous
Trial Profile

A 5-year post-marketing safety study for dalfampridine extended release tablets in multiple sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions

Most Recent Events

  • 27 Oct 2015 New trial record
  • 22 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial was presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.
  • 07 Oct 2015 According to an Acorda media release, 5-year post-marketing safety data from this trial will be presented at the 31st Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top